Ideas

August 24, 2018

Published by admin_auro at August 24, 2018

Categories

Ideas
Pain

Repurposing the anti-angina drug Ranolazine into an analgesic drug: Ranolazine-based activation of the PD-1 pathway for Pain therapy: Ranolazine increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 24/August/2018, 11.20 pm

Introduction: What they say: A recent study, from Institute of Neurobiology, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Collaborative Innovation Center for […]

August 24, 2018

Published by admin_auro at August 24, 2018

Categories

Ideas
Pain

The pregnancy hormone Relaxin relieves you of acute and chronic pain (No kidding): Relaxin-based activation of the PD-1 pathway for Pain therapy: Relaxin, a protein hormone that facilitates labor and relaxes the uterine musculature, increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 24/August/2018, 11.08 pm

Introduction: What they say: A recent study, from Institute of Neurobiology, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Collaborative Innovation Center for […]

August 24, 2018

Published by admin_auro at August 24, 2018

Categories

Combinatorial therapy for Deafness: A therapeutic mix encompassing Exemestane, Cholecalciferol, Ajoene and DIM (ECAD) increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration, improves hearing loss via upregulation of its target genes, 24/August/2018, 10.45 pm

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Combinatorial therapy for Deafness: A therapeutic mix encompassing Exemestane, Cholecalciferol, Ajoene and DIM (ECAD) increases the expression […]

August 24, 2018

Published by admin_auro at August 24, 2018

Categories

Serelaxin (SLX)-based therapy for cardiac hypertrophy and fibrosis: Serelaxin (SLX), a recombinant relaxin-2, decreases MiR-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 24/August/2018, 2.52 pm

Introduction: What they say: A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular […]